[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Latin America Molecular Diagnostics Market Assessment of 22 Countries-2021-2025 Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 100 Infectious, Genetic, Cancer, Forensic and Paternity Tests-Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

November 2021 | | ID: 2131B932226AEN
Venture Planning Group

US$ 14,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This new 22-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.

The report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget.

Highlights
  • Five-year test volume and sales forecasts
  • Strategic profiles of market players and start-up firms developing innovative technologies and products
  • Emerging technologies
  • Review of molecular diagnostic analyzers
  • Specific product and business opportunities for instrument and consumable suppliers
Rationale

The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Country Analyses

Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela

Market Segmentation Analysis
  • Sales and market shares of key suppliers of molecular diagnostic reagent kits and components in major markets.
  • Five-year test volume and sales forecasts for major applications, including:
    • Infectious Diseases
    • Forensic Testing
    • Cancer
    • Paternity Testing/HLA Typing
    • Genetic Diseases
    • Others
  • Five-year test volume and sales projections for over 30 NAT assays.
  • A comprehensive analysis of the sequencing market, by country and laboratory segment, including:
    • Industrial
    • Academic
    • Government
    • Commercial
  • Market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and suppliers in major countries.
Product/Technology Review
  • Comparison of leading molecular diagnostic analyzers marketed by Abbott, Beckman Coulter, BD, Bio-Rad, Gen-Probe, Roche, Tecan and other suppliers.
  • Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over 30 target/signal amplification methods.
  • Universities and research centers developing new molecular diagnostic technologies and products.
Competitive Assessments
  • Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.
  • Companies developing and marketing molecular diagnostics products, by test and application.
Opportunities and Strategic Recommendations
  • Specific new product development opportunities with potentially significant market appeal during the next five years.
  • Design criteria for new products.
  • Alternative market penetration strategies.
  • Potential market entry barriers and risks.
  • Business planning issues and concerns.
I. INTRODUCTION

II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VI. MARKET AND TECHNOLOGY REVIEW

A. DNA Sequencing
  1. Introduction
  2. Sequencing Methods
  3. Autoradiography
  4. The Human Genome Project
  5. Sequencing Automation
  6. Image Scanners
  7. Fluorescent Detection
  8. Gene Profiling
  9. Gene Expression
  10. Polymorphism Screening
  11. Protein Interaction Networks
B. DNA and RNA Probe Technologies
  1. Basic Principles
  2. Probe Preparation
  3. The DNA Probe Test
  4. Test Formats
  5. Labeling Techniques
  6. Amplification Methods
C. Detection Technologies
  1. Radioactive Methods
  2. Non-Isotopic Methods
D. Instrumentation
Review of latest analyzers from Abbott, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, Hologic,Qiagen, Roche, Siemens Healthineers, and others.
E. Biochips: Genosensors, Microarrays, Labs-on-the-Chip
    Liquid Transportation and Mixing
    Separation
    Reaction
    Detection
F. Pharmacogenomics
G. Major Applications
  1. Microbiology/Infectious Diseases
    a. Overview
    b. Major Infectious Diseases
    AIDS/HIV
    Adenovirus
    Aeromonads
    Anthrax/Bacillus Anthracis
    Arboviruses
    Babesiosis
    Bacillary Epithelioid Angiomatosis (BEA), other Bartonella (Rochalimaea)
    Blastocystis Hominis
    Brucella
    Campylobacter
    Candida
    Chagas Disease
    Chancroid
    Chlamydia
    Clostridium Difficile
    Coronaviruses
    Coxsackieviruses
    Creutzfeldt-Jakob’s Disease
    Cryptosporidium Parvum
    Cyclospora Cayetanensis
    Cytomegalovirus
    Ebola Virus
    E. Coli
    EchoVirus
    Encephalitis
    Enteroviruses
    Epstein-Barr Virus
    Giardia Lamblia
    Gonorrhea
    Granuloma Inguinale
    Hantavirus
    Helicobacter Pylori
    Hepatitis
    Herpes Simplex Virus
    Human Herpes Virus-6 (HHV-6)
    Influenza Viruses
    Legionella
    Lyme Disease
    Lymphogranuloma Venereum (LGV)
    Malaria
    Measles (Rubeola)
    Meningitis
    Microsporidium
    Mononucleosis
    Mumps
    Mycoplasma
    Papillomaviruses
    Parvovirus B19
    Pneumonia
    Polyomaviruses
    Pseudomonas Aeruginosa
    Rabies
    Respiratory Syncytial Virus(RSV)
    Rhinoviruses
    Rotavirus
    Rubella
    Salmonellosis
    Septicemia
    Shigellosis
    Staphylococcus Aureus
    Streptococci
    Syphilis
    Toxoplasmosis
    Trichomonas Vaginalis
    Tuberculosis
    Vibrio
    West Nile Virus
    Yersina
    West Nile Virus
    Yersina
  2. Cancer Testing
    a. Overview
    b. Major Cancer Types
    Prostate
    Lung
    Colon and Rectum
    Breast
    Skin
    Uterine
    Leukemia
    Oral
    c. Oncogenes
The report provides review of both current and emerging oncogenes, including:
    Abl/abl-bcr
    AIB1
    BCL-2
    BRCA1
    CD44
    C-fos
    C-myb
    C-myc
    CYP17
    Erb-B
    HPC1
    N-myc
    P40
    P51
    P53
    PIK3CA
    PTI-1
    Ras
    Reg
    Sis
    Src
  3. Genetic Diseases
    a. Overview
    b. Nucleic Acid Amplification
    c. Chromosome Imaging
    d. Genomics Technologies
    e. Proteomics Technologies
    f. Current Pharmacogenomic Tests
    g. Future Pharmacogenomic Testing
    h. Major Diseases
    Achondroplasia
    Autosomal Dominant Polycystic Kidney Disease
    Cancer
    Cosmetogenomics
    Cystic Fibrosis
    Down's Syndrome
    Duchenne and Becker Muscular Dystrophy
    Factor V (Leiden)
    Factor IX Deficiency
    Fragile X Syndrome
    Heart Disease
    Hemochomatosis
    Hemophilia
    Huntington's Disease
    Maternal-Fetal Incompatibility
    Multiple Endocrine Neoplasia
    Phenylketonuria (PKU)
    Polycystic Kidney Disease (PKD)
    Prenatal Screening
    Retinitis Pigmentosa
    Retinoblastoma
    Sickle Cell Anemia
    Spinal Muscular Atrophy
    Vitamin B12 Metabolism
    i. Social Issues and Concerns
  4. Forensic Testing
    a. Overview
    b. Multilocus and Single Locus Probes
    c. DNA Profile Data Banks
    d. Judicial Implementation
    e. Major Crime Categories
    f. Factors Contributing to the DNA Probe Market Expansion
    Technology Availability
    Use of Hair as Evidence
    g. Wildlife Forensics
  5. Paternity Testing/HLA Typing
  6. Other Applications
    a. Disease Susceptibility Testing
    b. Cardiovascular Diseases
    c. Diabetes
    d. Alzheimer's Disease
    e. Periodontal Disease
    f. Plasma Purification
    g. Organ Transplantation
    h. Water Contamination
    i. Other
H. Competing/complementing
  1. Monoclonal Antibodies/Immunoassays
  2. RNA Probes
  3. Two-Dimensional Electrophoresis
  4. Flow Cytometry

VII. 22-COUNTRY ANALYSES: VOLUME AND SALES FORECASTS--INFECTIOUS DISEASES, GENETIC

Diseases, Cancer, Forensic and Paternity Testing

VIII. COMPETITIVE ASSESSMENTS

The report provides strategic assessments of over 40 leading molecular diagnostics market players and start-up companies with innovative technologies and products, including:
Abbott, Agilent Technologies, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, DiaSorin, Eiken Chemical, Enzo, Fujirebio, Grifols, Hologic, Illumina, LabCorp/Sequenom, Leica Biosystems, Myriad Genetics, Ortho-Clinical Diagnostics, Qiagen, Quest Diagnostics, Quidel, Roche, Shimadzu, Siemens Healthineers, Sierra Molecular, Takara Bio, Tecan Group, Thermo Fisher, Wako and others.

IX. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING INNOVATIVE MOLECULAR DIAGNOSTIC TECHNOLOGIES AND PRODUCTS


More Publications